MDS-ES Parkinson's Disease Management: A Travel Throughout the Disease Course

Introduction

MDS-ES Parkinson's Disease Management: A Travel Throughout the Disease Course

Course Format

In-Person

Start Date

Fri, Jun 14, 2024

End Date

Sat, Jun 15, 2024

Course Location

Toulouse

Program Description

The course will take place Friday, June 14 and Saturday, June 15, 2024. Below, you will find a copy of course program that includes a detailed course schedule, address of the course venue, and instructions to completing the evaluation. Additionally, lectures will be posted as they are received from the program faculty. Lectures will remain available for 60 days post-course.

Registration is now closed. Please email education@movementdisorders.org with any questions.

Course Location

Toulouse France
Click here to view location map

Contact Us

MDS Education
education@movementdisorders.org

Course Overview (Course Overview, Agenda, & Fees)

Course Program & Schedule

Schedule as of June 6, 2024

PROGRAM OVERVIEW
Day 1: Friday, June 14 from 7:45 - 19:15
Day 2: Saturday, June 15 from 8:15 - 13:15

COURSE VENUE

University of Toulouse, Faculty of Medicine

Address: 37 All. Jules Guesde, 31000 Toulouse, France
Lecture Hall: Grand Amphithéâtre

LEARNING OBJECTIVES

Upon completion of this activity, learners will be able to:

1. Identify different Parkinson’s disease patients’ symptoms and related therapeutic needs

2. Design, review and modify a PD patient treatment plan

3. Relate the indications for a second-line treatments and key points for patients’ selection

4. Identify the principles of PD patients personalized approach

5. Relate the benefit and goals of non-pharmacological PD treatments

CERTIFICATE CLAIMING INSTRUCTIONS

Course certificate of attendance are available online. To access:

1. Visit https://education.movementdisorders.org.

2. Click “GET CERTIFICATE” in the upper right corner.

3. Once prompted enter the certificate code 779624. You will be prompted to fill out your course evaluation and upon completion, you will be able to download your certificate of attendance.

Commercial Support Acknowledgement

COURSE SUPPORT ACKNOWLEDGEMENT

The following companies have provided unrestricted medical education grants for the MDS-ES Parkinson’s Disease Management: A travel through the disease course:

AbbVie, Bial, ELIVIE, Medtronic, NHC, Orion Pharma, and Orkyn

Ethical MedTech Compliance

MDS-ES Parkinson's Disease Management: A travel throughout disease course, pharmacological, nonpharmacological and second-line approaches course has been found compliant by Ethical MedTech.

MDS submitted the MDS-ES Parkinson's Disease Management course to the Conference Vetting System (CVS) and has been assessed and deemed Compliant. Details are available here https://www.ethicalmedtech.eu/medtech-apps/cvs/view-event/EMT38144.

Any?sponsor showcasing pharmaceutical (or pharma-dependent) products is advised to consult the EFPIA Code of Practice and the MedTech Europe Code of Ethical Business Practice before applying. It is the exhibitor’s or sponsor’s?responsibility to comply with all national and international laws and regulations that pertain to its?particular industry, and to ensure that a compliance officer has approved the specific sponsorship items prior to the application.?

MDS is not liable in any way for sponsors not complying with legal, ethical and industry standards.

Course Lectures & Supplemental Materials

DAY 1, Friday, June 14

1.01 Biological Definition, Stages and Diagnostic Criteria for PD_Joaquim Ferreira.pdf

1.02 Early PD Management_David Devos.pdf
1.03 First-Line Approach for Motor and Non-Motor Fluctuations and Dyskinesia_Jean-Philippe Azulay.pdf
1.04 Pain, Fatigue and Sleep Disorders Management_Jean-Philippe Azulay.pdf
1.05 Dysautonomia Management_Anne Pavy-Le Traon.pdf
1.06 Mood and Neuropsychiatric Disorders Management_Stephane Thobois.pdf
1.07 Speech Disorders_Carolie Moreau.pdf
1.08 Postural Disorders_Carlo Alberto Artusi.pdf
1.09 Management of Gait and Exercise_Bas Bloem.pdf
1.10 Genetics in PD and Treatment Implications_Enza Maria Valente.pdf
1.11 Neuroptotection in PD_David Devos.pdf
1.12 Clinical Trials in Parkinson's Disease_Jean-Christophe Corvol.pdf

DAY 2, Saturday, June 15

2.1 Infusion Therapies in PD_Fabienne Ory Magne.pdf
2.02 Deep Brain Stimulation_Anna Castrioto.pdf
2.03 Neuromodulation vs Lesional Approaches_Carlo Alberto Artusi.pdf
2.05 Treatment Approaches in Late Stage PD_Margherita Fabbri.pdf
2.06 Palliative Care Concepts in PD_Joaquim Ferreira.pdf
2.07 Wearable Sensors in the Management of PD_Caroline Moreau.pdf